BIONEER CORPORATION

An in vitro 3D cancer platform offering tailored tumor models that simulate the complexity and cellular diversity of solid tumors as they appear in the human body, combined with the eSight® system for real-time cell analysis (RTCA).

An in vitro 3D cancer platform offering tailored tumor models that simulate the complexity and cellular diversity of solid tumors as they appear in the human body. Composed of spheroids with fibroblasts and cancer cells to mimic the tumor microenvironment, providing predictive insights into drug efficacy earlier in development.

Gene editing technologies and protocols for modifying T-cells, NK cells, macrophages, and differentiation of human induced pluripotent stem cells to immune cells for novel immune and cancer models.

Cell lines generated using CRISPR/Cas9 or TALEN technology for in vitro modelling, with comprehensive quality control analysis to ensure reliable and precise results.

Bioneer's Molecular Histology laboratory offers advanced immunohistochemistry (IHC), RNA in situ hybridization (ISH), and in situ Proximity Ligation Assays (isPLA) with automated processes and AI/ML-guided interpretations for spatial biology insights.

Commercial manufacturing of GMP-grade process proteins and drug substances for non-clinical use with dedicated up- and downstream suites, including 50 L stainless steel fermentors and advanced purification systems.

Comprehensive CDMO services supporting protein development from initial concept through to production, including microbial and mammalian platforms with upstream and downstream processing, characterization, and formulation development.

Bioneer has developed and produced recombinant proteins using both mammalian and microbial hosts, continuously expanding and refining protein manufacturing technologies and processes.

Efficient CHO-based expression platform producing multiple modalities including monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), bispecifics, and more, with parallel screening capabilities to accelerate drug candidate development.

Human iPSC-based Parkinson’s disease models and associated in vitro systems to support drug discovery, target validation, and preclinical development. Models capture key disease-relevant mechanisms including α-synuclein aggregation, inflammation, and mitochondrial dysfunction.

An in vitro assay using human iPSC-derived dopaminergic or cortical neurons to induce and measure alpha-synuclein aggregation for Parkinson’s and dementia research, employing a sensitive FRET-based readout combined with phospho-specific α-synuclein antibodies.

Bioneer specialises in generating various neuronal cell types through traditional and accelerated differentiation techniques using inducible transcription factors such as NGN2. They also develop critical glial cell types and advanced co-culture systems combining neuronal and glial cells for more accurate human brain models.

A proprietary license-free microbial expression system specialized for E. coli used in GMP-grade protein production.

The Bioneer BION-CHO 6.0 System™ is a mammalian recombinant protein expression system using proprietary vectors for CHO-DG44 cells, achieving high expression levels and stable production over 60 generations, with titers up to 6 g/L for monoclonal antibodies.

Customizable characterization packages for recombinant proteins analyzing purity, identity, structure, aggregation, and stability from microbial or mammalian expression systems.

Commercial supply of high-quality process enzymes and ancillary proteins used in manufacturing vaccines, APIs, and cell- and gene therapies, including production of difficult proteins for pre-clinical studies.

Custom-designed package tailored to support biotech companies in early-phase drug development, focusing on CMC development and recombinant protein production in mammalian systems.

A service providing precise, detailed electrophysiological readouts with increased robustness for neuronal responses using high-density multielectrode arrays.

Customized downstream process development and purification services for proteins, including rapid material provision and full-scale process development optimized for cGMP manufacturing.

Robust protocols to generate iPSC-derived microglia carrying Alzheimer's disease-related genetic variants in monoculture and co-culture with neurons, validated for key microglia markers and functional assays including cytokine release and phagocytosis.

A proprietary license-free microbial expression system specialized for Lactococcus lactis used in GMP-grade protein production.

Efficient, scalable purification solutions tailored to specific proteins and expression systems, achieving >99% purity with optimized multistep workflows.

Precision genome engineering of mammalian cells to improve productivity, quality, and activity of biologically produced proteins, including therapeutic proteins.

A proprietary in vitro model that accurately simulates the complex dynamic biochemical composition and peristalsis of the human stomach to study oral dosage form behavior and drug release under simulated gastro-intestinal conditions.

A high-throughput bioreactor system used to accelerate upstream process development and de-risk scale-up for biologics production.

Development of formulation technologies and principles for small molecules, peptides, and biologics including biologics, focusing on targeted delivery approaches and solutions for poorly soluble compounds.

Strategies and protocols to increase speed and success rates of protein refolding processes, optimizing key parameters based on protein characteristics to ensure functionality of proteins expressed in E. coli.